Hemagen Diagnostics Inc
Hemagen Diagnostics, Inc., a biotechnology company, provides human and veterinary clinical diagnostic solutions worldwide. The company develops, manufactures, and markets VIRGO, a human clinical diagnostic line of immunoassays for the diagnosis of autoimmune and infectious diseases, and acute phase proteins. Its human diagnostics products also comprise Universal IFA components; supplies, controls… Read more
Hemagen Diagnostics Inc (HMGN) - Total Liabilities
Latest total liabilities as of September 2012: $6.00 Million USD
Based on the latest financial reports, Hemagen Diagnostics Inc (HMGN) has total liabilities worth $6.00 Million USD as of September 2012.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Hemagen Diagnostics Inc - Total Liabilities Trend (1993–2012)
This chart illustrates how Hemagen Diagnostics Inc's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
Hemagen Diagnostics Inc Competitors by Total Liabilities
The table below lists competitors of Hemagen Diagnostics Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Now Corp
PINK:NWPN
|
USA | $36.42 Million |
|
Patient Access Solutions Inc
PINK:PASO
|
USA | $2.45 Million |
|
ComF5 International Inc
PINK:CMFV
|
USA | $4.00 Million |
|
Legends Business Grp
PINK:LGBS
|
USA | $5.93 Million |
|
Diamond Discov Intl
PINK:DMDD
|
USA | $2.09 Million |
|
D7 Enterprises Inc
PINK:DGIF
|
USA | $3.27 Million |
|
All American Pet Co
PINK:AAPT
|
USA | $5.85 Million |
|
Energy 1 Corp
PINK:EGOC
|
USA | $5.23 Million |
Liability Composition Analysis (1993–2012)
This chart breaks down Hemagen Diagnostics Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 1.07 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | -1.69 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 2.46 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Hemagen Diagnostics Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Hemagen Diagnostics Inc (1993–2012)
The table below shows the annual total liabilities of Hemagen Diagnostics Inc from 1993 to 2012.
| Year | Total Liabilities | Change |
|---|---|---|
| 2012-09-30 | $6.00 Million | +7.61% |
| 2011-09-30 | $5.58 Million | +6.84% |
| 2010-09-30 | $5.22 Million | -5.12% |
| 2009-09-30 | $5.50 Million | -6.17% |
| 2008-09-30 | $5.86 Million | +4.09% |
| 2007-09-30 | $5.63 Million | +10.48% |
| 2006-09-30 | $5.10 Million | -19.81% |
| 2005-09-30 | $6.36 Million | +18.50% |
| 2004-09-30 | $5.36 Million | +17.50% |
| 2003-09-30 | $4.56 Million | +19.60% |
| 2002-09-30 | $3.82 Million | +5.56% |
| 2001-09-30 | $3.62 Million | -32.39% |
| 2000-09-30 | $5.35 Million | -26.74% |
| 1999-09-30 | $7.30 Million | +23.73% |
| 1998-09-30 | $5.90 Million | +293.33% |
| 1997-09-30 | $1.50 Million | -37.50% |
| 1996-09-30 | $2.40 Million | -55.56% |
| 1995-09-30 | $5.40 Million | +145.45% |
| 1994-09-30 | $2.20 Million | +100.00% |
| 1993-09-30 | $1.10 Million | -- |